VAS 2381

Drug Profile

VAS 2381

Alternative Names: VAS-2381

Latest Information Update: 19 Sep 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator vasopharm BIOTECH
  • Class Vasoprotectives
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cerebral ischaemia

Most Recent Events

  • 05 Aug 2005 Discontinued - Preclinical for Cerebral ischaemia in Germany (unspecified route)
  • 21 Aug 2003 Preclinical trials in Cerebral ischaemia in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top